Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study

Respiratory Research

Table 1 Characteristics of Analyzed Population at Year 1 (n = 5,307) with 628 deaths at up to 15 years of follow-up

	N	%	Person-Years of Follow-up	Deaths per 1,000 Person Years
Sex
Female	1993	37.6	24,764	8.3
Male	3314	62.4	40,708	10.4
Age Group, Years
35-39	522	9.8	6,610	3.8
40-49	2099	39.6	26,350	5.5
50-59	2494	47.0	30,267	13.7
60+	192	3.6	2,245	18.7
Body Mass Index, kg/m²
< 25	2528	47.6	31,168	9.5
25- 30	2082	39.2	25,791	9.1
> = 30	697	13.1	8,513	11.5
Education, Years
< 12	632	11.9	7,720	13.0
12	1592	30.0	19,629	10.0
> 12	3083	58.1	38,123	8.7
Race
White	5108	96.3	63,117	9.2
Black	199	3.7	2,355	20.8
Smoking Status
Former	1439	27.1	17,966	7.0
Intermittent	628	11.8	7,752	9.5
Current	3240	61.1	39,754	10.8
Randomization Group
Intervention, Ipratroprium	1793	33.8	22,141	8.9
Intervention, Placebo	1785	33.6	22,108	9.0
Control	1729	32.6	21,223	11.0
Stage (pre-bronchodilator)*
Stage 3 or 4	67	1.3	799	15.0
Stage 2	3432	64.7	42,208	10.7
Stage 1	1354	25.5	16,852	7.3
Restricted	69	1.3	840	9.5
Normal	385	7.3	4,773	6.7
Stage (post-bronchodilator)*
Stage 3 or 4	19	0.4	224	13.4
Stage 2	2540	47.9	31,126	12.1
Stage 1	1565	29.5	19,386	7.8
Restricted	125	2.4	1,487	12.1
Normal	1058	19.9	13,249	5.8

ISSN: 1465-993X